Get the Stockscreener App
14.27
1.08%
-0.10
Mineralys Therapeutics Inc stock is traded at $14.27, with a volume of 24,373.
It is down -1.08% in the last 24 hours and down -11.32% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$14.37
Open:
$14.55
24h Volume:
24,373
Relative Volume:
0.03
Market Cap:
$1.04B
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-5.2271
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
-2.24%
1M Performance:
-11.32%
6M Performance:
+44.02%
1Y Performance:
+8.51%
1-Day Range:
$14.21
$14.55
1-Week Range:
$13.44
$14.70
52-Week Range:
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
14.21 | 1.04B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.21 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.39 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.31 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
556.37 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.00 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial - Investing.com Canada
Mineralys enhances lorundrostat data package ahead of planned NDA - The Pharma Letter
Mineralys Therapeutics (MLYS): Analyst Reiterates Buy Rating and Price Target | MLYS Stock News - GuruFocus
Promising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment Appeal - TipRanks
Mineralys reports positive phase 2 data for lorundrostat in CKD By Investing.com - Investing.com South Africa
Mineralys reports positive phase 2 data for lorundrostat in CKD - Investing.com Australia
Mineralys Therapeutics Shares Climb on Strong Results from Kidney Disease Trial - MSN
Positive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating - TipRanks
Promising Phase 2 Trial Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating and $42 Price Target - TipRanks
Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps - Benzinga
Transcript : Mineralys Therapeutics, Inc.Special Call - MarketScreener
Mineralys Therapeutics stock jumps after positive kidney disease trial data By Investing.com - Investing.com South Africa
Mineralys Therapeutics' Phase 2 Explore-CKD Study Of Lorundrostat Meets Primary Goal - Nasdaq
Mineralys Phase 2 Trial of Hypertension, Kidney Disease Drug Meets Primary Endpoint; Shares Up Pre-Bell - MarketScreener
Mineralys Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria - GlobeNewswire
Breakthrough: Mineralys Phase 2 Drug Achieves Dual Success in Blood Pressure and Kidney Protection Trial - Stock Titan
How the (MLYS) price action is used to our Advantage - news.stocktradersdaily.com
Mineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street Zen - Defense World
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Jefferies Initiates Coverage on Mineralys Therapeutics (MLYS) with Hold Rating | MLYS Stock News - GuruFocus
Jefferies Initiates Coverage on Mineralys Therapeutics With Hold Rating, $15 Price Target - MarketScreener
Jefferies initiates Mineralys Therapeutics stock with hold rating By Investing.com - Investing.com Nigeria
Jefferies initiates Mineralys Therapeutics stock with hold rating - Investing.com
Cautious Outlook for Mineralys Therapeutics Amid Market Challenges and Competitive Pressures - TipRanks
Bank of America Corp DE Has $1.33 Million Stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
BNP Paribas Financial Markets Buys Shares of 3,895 Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS) - Seeking Alpha
ProShare Advisors LLC Takes Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Purchased by Deutsche Bank AG - Defense World
Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat - MSN
Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting - MSN
Mineralys announces late-breaking presentation of data from Launch-HTN trial - Yahoo Finance
Buy Rating for Mineralys Therapeutics: Strong Clinical Results and Growth Prospects Highlight Significant Upside Potential - TipRanks
Mineralys reports outcomes from trial of lorundrostat for hypertension - Yahoo Finance
MLYS: Promising Phase 3 Results for Hypertension Treatment | MLYS Stock News - GuruFocus
Northern Trust Corp Purchases 1,688 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) - The Manila Times
Mineralys Therapeutics Reports Positive Results from Phase 3 Launch-HTN Trial of Lorundrostat for Uncontrolled Hypertension - Nasdaq
These 3 Artificial Intelligence (AI) Stocks Look Cheap Right Now - The Globe and Mail
Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12 - marketscreener.com
Mineralys Therapeutics Announces Late-Breaking Presentation - GlobeNewswire
Breakthrough Phase 3 Results: New Drug Cuts Blood Pressure by 19 mmHg in Largest Hypertension Trial - Stock Titan
Mineralys Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going - sharewise
Mineralys to present lorundrostat trial data at ESH 2025 - Investing.com Australia
Mineralys to present lorundrostat trial data at ESH 2025 By Investing.com - Investing.com South Africa
Mineralys Announces Late-Breaking Presentation Of Phase 3 Launch-HTN Trial - marketscreener.com
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection - The Manila Times
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mineralys Therapeutics Inc Stock (MLYS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rodman David Malcom | Chief Medical Officer |
Jun 13 '25 |
Sale |
14.60 |
11,366 |
165,931 |
101,651 |
0.09%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):